DHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Danaher Corp (DHR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite short-term technical weakness, the stock has strong institutional and congressional support, positive long-term growth prospects in bioprocessing, and favorable sentiment from analysts who maintain buy ratings with adjusted price targets. The options data also suggests a bullish sentiment. This aligns with the user's preference for long-term investing.
The technical indicators are bearish in the short term. The MACD is negatively expanding (-0.233), the RSI is neutral at 36.773, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 176.019), which could act as a floor for further downside.
Congress members have made significant purchases of DHR stock in the last 90 days, with 6 buy transactions totaling $0.6M to $9.0M, indicating strong confidence.
Analysts from HSBC, DZ Bank, Citi, and RBC Capital maintain buy ratings with price targets ranging from $200 to $230, citing recovery in bioprocessing and long-term growth potential.
Options market sentiment is bullish, with a low put-call ratio and increasing open interest.
Short-term technical indicators are bearish, with the stock trading below key moving averages and MACD showing negative momentum.
Recent downgrades by Wolfe Research and Piper Sandler reflect cautious sentiment due to sector headwinds and competition.
The stock's pre-market performance (-1.37%) and regular market decline (-0.33%) indicate near-term weakness.
No financial data available for the latest quarter. However, analysts highlight Danaher's fiscal 2026 core growth guidance and a potential recovery in bioprocessing, which supports long-term revenue growth.
Analysts have mixed views but lean positive. HSBC, DZ Bank, Citi, and RBC Capital maintain buy ratings with price targets between $200 and $230. Piper Sandler and Wolfe Research have neutral ratings, citing sector headwinds and competition. Overall, the consensus reflects cautious optimism for long-term growth.
